Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI

A literature search along with genetic study was conducted to define the risk of major adverse cardiovascular outcomes of reduced-function CYP2C19 genetic variants in patients treated with clopidogrel. The findings from meta-analysis demonstrated that common genetic variants in the CYP2C19 gene are associated with almost 1 in 3 patients not receiving ideal protection from ischemic events when treated with standard doses of clopidogrel for PCI.